Drug Profile
Research programme: therapeutic antibodies - Boehringer Ingelheim/MorphoSys
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; MorphoSys
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Germany
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Germany